Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy

Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of translational research in the field, OV therapy is pois...

Full description

Bibliographic Details
Main Authors: Christian Bressy, Eric Hastie, Valery Z. Grdzelishvili
Format: Article
Language:English
Published: Elsevier 2017-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
oncolytic virus
virotherapy
tumor suppressor
TP53
tumor protein p53
p53
p63
p73
cancer gene therapy
combination treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770517300098

Internet

http://www.sciencedirect.com/science/article/pii/S2372770517300098

Similar Items